The abstract is read at the publisher; the summary is JClub's.
TRIM5 and TRIM56 restrict dengue virus serotype 2 infection, while TRIM69 enhances it, with TRIM5/TRIM56 linked to lower viral RNA and protein levels.
- Why it matters: Cellular resistance mechanisms against DENV2 are needed to guide antiviral therapeutic development, yet how specific TRIM proteins target DENV2 remains unclear and conflicting.
- What they did: Using TRIM overexpression and CRISPR/Cas9 loss-of-function in infected cells, the study measured infection outcomes and viral RNA/protein levels, then tested NS2B3-mediated antagonism via virus-free NS2B3 assays and reciprocal abundance changes.
- The result: TRIM56 downregulated NS2B3 protease complex levels, and DENV2 NS2B3 reduced TRIM56 and TRIM69 abundance independently of protease activity; TRIM56 RING mutants retained partial antiviral activity, implying proteasome- and lysosome-independent TRIM56–NS2B3 reciprocal downmodulation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.